Junshi Biosciences

Coherus, Junshi’s PD-1 blocker Loqtorzi aces phase III liver cancer trial
BioSpace
Thu, 06/13/24 - 11:23 am
Coherus Biosciences
Junshi Biosciences
Loqtorzi
liver cancer
Coherus hits FDA hurdles for PD-1 drug, Neulasta biosimilar on-body injector
Fierce Pharma
Mon, 09/25/23 - 07:56 pm
Coherus Biosciences
Neulasta
biosimilars
FDA
Junshi Biosciences
Trailing AstraZeneca and Merck, Junshi reports phase 3 ovarian cancer success for Lynparza rival
Fierce Biotech
Wed, 04/12/23 - 11:39 am
Junshi Biosciences
PARP inhibitors
ovarian cancer
Merck
AstraZeneca
Lynparza
Junshi's lipid lowering drug hits phase 3 goals, teeing up challenge to Amgen, Sanofi in growth market
Fierce Biotech
Tue, 02/28/23 - 10:03 am
Junshi Biosciences
Amgen
Sanofi
China
clinical trials
PCSK9 inhibitors
It's CRL Day at the FDA as Axsome, Junshi and Coherus Get Bad News
BioSpace
Mon, 05/2/22 - 11:44 am
FDA
complete response letter
Junshi Biosciences
Coherus Biosciences
Axsome Therapeutics
migraines
AXS-07
Racing ahead of Merck and Innovent, Junshi declares PhIII success on cancer that won them 'breakthrough' status
Endpoints
Tue, 09/29/20 - 11:51 am
Junshi Biosciences
China
Merck
Innovent
nasopharyngeal carcinoma
toripalimab
China’s Junshi hits immuno-oncology milestone with breakthrough designation from FDA
MedCity News
Sat, 09/12/20 - 10:22 pm
China
Junshi Biosciences
immuno-oncology
toripalimab
nasopharyngeal carcinoma
FDA
Lilly starts second COVID-19 antibody test with partner Junshi Biosciences, eyes combo trials
Fierce Biotech
Mon, 06/8/20 - 11:34 pm
Eli Lilly
Junshi Biosciences
COVID-19
antibodies
COVID-19: Lilly ramps up to beat the virus with neutralizing antibodies as scientists raise worries
Fierce Biotech
Thu, 05/7/20 - 10:39 am
Eli Lilly
Junshi Biosciences
antibodies
COVID-19
Eli Lilly, Junshi collaborate to develop antibody therapies for Covid-19 disease
Pharmaceutical Business Review
Tue, 05/5/20 - 10:42 am
Eli Lilly
Junshi Biosciences
COVID-19
antibodies
R&D